about
A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomationExpression and purification of functional human vascular endothelial growth factor-a121; the most important angiogenesis factor.Inducible VEGF expression by human embryonic stem cell-derived mesenchymal stromal cells reduces the minimal islet mass required to reverse diabetes.Efficiency of Plasmocin™ on various mammalian cell lines infected by mollicutes in comparison with commonly used antibiotics in cell culture: a local experienceInhibition of angiogenesis in human endothelial cell using VEGF specific nanobody.Selection and Characterization of Specific Nanobody Against Human Immunoglobulin G.Soluble Expression and Characterization of a New scFv Directed to Human CD123.Production and Characterization of Novel Camel Single Domain Antibody Targeting Mouse Vascular Endothelial Growth Factor.Functional recombinant extra membrane loop of human CD20, an alternative of the full length CD20 antigenA Model to Study the Phenotypic Changes of Insect Cell Transfection by Copepod Super Green Fluorescent Protein (cop-GFP) in Baculovirus Expression SystemDevelopment of a novel engineered antibody targeting human CD123.Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell.Development and Characterization of a New Antipeptide Monoclonal Antibody Directed to Human CD20 Antigen.Epidermal growth factor receptor targeting alters gene expression and restores the adhesion function of cancerous cells as measured by single cell force spectroscopy.Antigenic assessment of a recombinant human CD90 protein expressed in prokaryotic expression system.Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth.
P50
Q33576215-A2952969-3DCF-4071-A0E8-1651925A5C67Q34063852-02FFCAFD-139D-4F2A-B308-CE8B219CC396Q35227182-CA75B58F-6CAC-4825-AC4B-3CE01E8898A3Q35552326-6868939F-D92C-4433-A888-59DFEA71393BQ35553928-03047B85-C40D-48D3-A136-C445F886DDD7Q35668270-446E18B3-0D99-4FDF-B2D5-E0D050AA6D32Q35889617-AE3AEF44-1D81-4AAD-A235-A725E68B79E4Q36014353-A10BC6C5-4B75-4ED1-83AB-4DCFF3E1ED4DQ36777171-E287E9BD-7B97-4459-BD1B-C2867C90A926Q37106298-61B84F82-55A1-43BC-8B86-ED7E51A80961Q38772453-FEB5B5E5-8A8F-4D03-A2E2-1326F75E3CE0Q38784661-623AEB6D-6605-41AD-894F-0A23F0D085B6Q38836589-F61BCBDA-D562-4E71-B5B1-4235040CDF10Q39328784-FF2612C0-A9CF-4F2F-B82F-FCA6B2CFC4B3Q40617332-6FBC48D0-7A10-484B-BB30-3448F33C088DQ45176272-0BFF4C18-1339-4AA3-B3E2-EEBCB70F27FC
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mahdi Habibi-Anbouhi
@ast
Mahdi Habibi-Anbouhi
@en
Mahdi Habibi-Anbouhi
@es
Mahdi Habibi-Anbouhi
@sl
type
label
Mahdi Habibi-Anbouhi
@ast
Mahdi Habibi-Anbouhi
@en
Mahdi Habibi-Anbouhi
@es
Mahdi Habibi-Anbouhi
@sl
prefLabel
Mahdi Habibi-Anbouhi
@ast
Mahdi Habibi-Anbouhi
@en
Mahdi Habibi-Anbouhi
@es
Mahdi Habibi-Anbouhi
@sl
P1053
Q-1681-2016
P106
P1153
47961960500
P21
P31
P3829
P496
0000-0002-3151-152X
P569
2000-01-01T00:00:00Z